Enliven Therapeutics (ELVN) Interest Coverage Ratio Growth (1y) (2020 - 2026)
Enliven Therapeutics (ELVN) Interest Coverage Ratio Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 787.12% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -100.36% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 73.00% |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | 29.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.94% |
| Dec 31, 2025 | 52.06% |
| Sep 30, 2025 | 84.49% |
| Jun 30, 2025 | 83.92% |
| Mar 31, 2025 | -24.90% |
| Dec 31, 2024 | -95,889.91% |
| Sep 30, 2024 | -449.06% |
| Jun 30, 2024 | -63.89% |
| Mar 31, 2024 | 62.76% |
| Dec 31, 2023 | -22.51% |
| Sep 30, 2023 | -38.41% |
| Jun 30, 2023 | -771.71% |
| Mar 31, 2023 | -1,971.64% |
| Dec 31, 2022 | 99.83% |
| Sep 30, 2022 | 22.98% |
| Jun 30, 2022 | -490.02% |
| Mar 31, 2022 | -1,693.94% |
| Dec 31, 2021 | -666.21% |
| Sep 30, 2021 | -10,448.09% |
| Jun 30, 2021 | -1,285.93% |